Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Sonoma Pharmaceuticals (NASDAQ:SNOA) reported strong Q2 FY2025 results with significant improvements across key metrics. Revenue increased 31% to $3.6 million, driven by growth in US (14%), Europe (25%), and Latin America (79%). The company reduced its net loss by 59% to $0.6 million, while achieving positive cash flows from operations of $0.35 million. Gross profit margin improved to 38% from 36% year-over-year. The company strengthened its market position through new distribution agreements for wound care products in the US and Canada, and received FDA clearance for expanded eye care and dermatological product indications.

Positive

Revenue increased 31% YoY to $3.6 million
Net loss decreased 59% YoY to $0.6 million
Positive operating cash flow of $0.35 million
Gross profit margin improved to 38% from 36%
Cash position increased by $2 million YoY to $4.1 million
Strong regional growth: US +14%, Europe +25%, Latin America +79%

Negative

Still operating at a net loss of $0.6 million
US revenue declined 6% for the six-month period

News Market Reaction

+2.10%

1 alert

+2.10% News Effect

On the day this news was published, SNOA gained 2.10%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

11/07/2024 - 08:45 AM

Revenue increased 31% for the quarter compared to same period prior year
Positive cash flows from operations of $0.35 million for the quarter
Net loss improved 59% for the quarter compared to same period prior year
Net loss per share improved 90% for the quarter compared to same period prior year

BOULDER, CO / ACCESSWIRE / November 7, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced financial results for its second fiscal quarter ended September 30, 2024.

"Our results this quarter reflect the diligent efforts by Sonoma's team to grow our business and drive toward profitability," said Amy Trombly, CEO of Sonoma. "Revenues were up 31%, our net loss improved by 59%, and we saw positive cash flows from our operations for the quarter. Additionally, we set the stage for future growth with a new partnership to distribute our wound care products in the U.S. and Canada, and received a new FDA clearance to strengthen the indications for our eye care and dermatological products."

Business Highlights

Sonoma continued to improve and expand its product offerings and regulatory approvals, and to grow its distribution network by entering into new partnerships:

On August 19, 2024, Sonoma entered into a distribution agreement with a leading global healthcare distributor for the marketing and distribution of its wound care products in the United States. On October 17, 2024, Sonoma entered into an amendment this agreement to allow for the marketing and distribution of its wound care products in Canada, and to add over-the-counter wound care products for sale in both countries.

On September 13, 2024, Sonoma received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microcyn technology-based solution, including specific over-the-counter indications for the face, eyelid and eyelashes.

On September 11, 2024, Sonoma announced an expanded prescription and over-the-counter eye care product line, featuring a refreshed design and improved packaging for Ocucyn^® Eyelid & Eyelash Cleanser.

On August 26, 2024, Sonoma and its partner, the MicroSafe Group DMCC, announced that the Australian Therapeutic Goods Administration (TGA) had approved extended claims for Nanocyn^® Disinfectant and Sanitizer for effective use against Candida auris (C. auris) and Clostritium Difficile (C. diff.).

Results for the Quarter Ended September 30, 2024

Total revenues for the quarter ended September 30, 2024 of $3.6 million increased by $0.9 million, or 31%, as compared to $2.7 million for the same period last year. Revenues in the United States increased 14%, primarily as a result of an increase in sales of dermatology and eye care products. Revenues in Europe increased 25% compared to the same period last year, as the result of increased demand for Sonoma's products. Revenues in Latin America increased 79% as a result of an increase in manufacturing orders. Revenues increased in Asia and decreased in Rest of World when compared to the same period last year. Revenues from these regions tend to be choppy when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs when ordering larger quantities.

During the quarter ended September 30, 2024, Sonoma reported revenues of $3.6 million and cost of revenues of $2.2 million resulting in gross profit of $1.4 million, or 38% of revenue, compared to a gross profit of $1.0 million, or 36% of revenue in the same period last year. The increase is primarily the result of an increase in revenue as compared to last year.

Total operating expenses during the quarter ended September 30, 2024 were $2.2 million, approximately flat with the prior year.

Net loss for the three months ended September 30, 2024 of $0.6 million decreased by $0.9 million, or 59%, when compared to a net loss of $1.5 million for the three months ended September 30, 2023. The decrease in net loss is primarily related to the increased revenues and gross profit described above and exchange rate impacts. EBITDA loss for the three months ended September 30, 2024 of $0.6 million decreased $0.4 million, compared to an EBITDA loss of $1.0 million for the same period last year.

Results for the Six Months Ended September 30, 2024

Total revenues for the six months ended September 30, 2024 of $7.0 million increased by $0.8 million, or 13%, as compared to $6.2 million for the same period last year. Revenues in Europe increased 23% compared to the same period last year as the result of increased demand for Sonoma's products. Revenues in Latin America increased 80% as a result of an increase in manufacturing orders. Revenues in the United States declined 6% primarily as a result of a fluctuations in timing of orders for over-the-counter animal health products. Revenues increased in Asia and decreased in Rest of World when compared to the same period last year. Revenues from these regions tend to be choppy when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs when ordering larger quantities.

During the six months ended September 30, 2024, Sonoma reported revenues of $7.0 million and cost of revenues of $4.3 million, resulting in gross profit of $2.7 million, or 38% of revenue, compared to a gross profit of $2.2 million, or 36% of revenue in the same period last year. The increase is the result of changes in overall product mix and territories to which products were shipped.

Total operating expenses during the six months ended September 30, 2024 were $4.7 million and approximately flat with prior year.

Net loss for the six months ended September 30, 2024 of $1.8 million decreased by $1.1 million, or 38%, when compared to a net loss of $2.9 million for the six months ended September 30, 2023. The decrease in net loss is primarily related to the increased revenues and gross profit described above and exchange rate impacts. EBITDA loss for the six months ended September 30, 2024 of $1.7 million decreased $0.3 million, compared to an EBITDA loss of $2.0 million for the same period last year.

As of September 30, 2024, Sonoma had cash and cash equivalents of $4.1 million, an increase of $1.5 million from the prior quarter, and an increase of $2 million compared to the same period last year.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "reduce," "develop," "aim," and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to the recent pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™, Microcyn^®, Ocucyn^®, and Nanocyn^® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.

ir@sonomapharma.com

Website: https://www.sonomapharma.com

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)

	September 30, 2024			March 31, 2024
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	4,078		$	3,128
Accounts receivable, net		3,157			2,898
Inventories, net		2,837			2,719
Prepaid expenses and other current assets		1,929			3,541
Current portion of deferred consideration, net of discount		220			262
Total current assets		12,221			12,548
Property and equipment, net		255			365
Operating lease, right of use assets		162			286
Deferred tax asset		792			1,145
Deferred consideration, net of discount, less current portion		179			330
Other assets		76			66
Total assets	$	13,685		$	14,740

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	770		$	607
Accrued expenses and other current liabilities		2,022			2,113
Deferred revenue, current portion		319			478
Short-term debt		82			323
Operating lease liabilities, current portion		116			198
Total current liabilities		3,309			3,719
Deferred revenue, net of current portion		45			87
Withholding tax payable		4,933			4,710
Operating lease liabilities, less current portion		46			87
Total liabilities		8,333			8,603
Commitments and Contingencies (Note 5)
Stockholders' Equity:
Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at September 30, 2024 and March 31, 2024, respectively, no shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively		-			-
Common stock, $0.0001 par value; 50,000,000 and 24,000,000 shares authorized at September 30, 2024 and March 31, 2024, respectively, 1,338,615 and 780,371 shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively		-			-
Additional paid-in capital		205,651			203,209
Accumulated deficit		(196,102	)		(194,349	)
Accumulated other comprehensive loss		(4,197	)		(2,723	)
Total stockholders' equity		5,352			6,137
Total liabilities and stockholders' equity	$	13,685		$	14,740

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)


	Three Months Ended September 30,						Six Months Ended September 30,
	2024			2023			2024			2023
Revenues	$	3,579		$	2,731		$	6,970		$	6,158
Cost of revenues		2,218			1,741			4,303			3,964
Gross profit		1,361			990			2,667			2,194
Operating expenses
Research and development		506			536			976			861
Selling, general and administrative		1,705			1,662			3,714			3,781
Total operating expenses		2,211			2,198			4,690			4,642
Loss from operations		(850	)		(1,208	)		(2,023	)		(2,448	)
Other income (expense), net		387			(90	)		563			(301	)
Loss from operations before income taxes		(463	)		(1,298	)		(1,460	)		(2,749	)
Income tax expense		(147	)		(186	)		(293	)		(153	)
Net loss	$	(610	)	$	(1,484	)	$	(1,753	)	$	(2,902	)

Net loss per share: basic and diluted	$	(0.59	)	$	(5.75	)	$	(1.86	)	$	(11.47	)
Weighted-average number of shares: basic and diluted		1,034			258			943			253

Other comprehensive loss
Net loss	$	(610	)	$	(1,484	)	$	(1,753	)	$	(2,902	)
Foreign currency translation adjustments		(593	)		(213	)		(1,474	)		298
Comprehensive loss	$	(1,203	)	$	(1,697	)	$	(3,227	)	$	(2,604	)

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES
(In thousands)
(Unaudited)

	Three Months Ended September 30,						Six Months Ended September 30,
	2024			2023			2024			2023
(1) Net loss adjusted for non-cash items and one-time events or EBITDA loss:
GAAP net loss as reported	$	(610	)	$	(1,484	)	$	(1,753	)	$	(2,902	)

Non-cash adjustments:
Stock-based compensation		14			130			121			307
Non-cash foreign exchange transaction losses (gains)		(225	)		108			(402	)		367
Income tax expense		147			186			293			153
Depreciation and amortization		35			45			74			90
Non-GAAP net loss adjusted for non-cash items and one-time events or EBITDA loss	$	(639	)	$	(1,015	)	$	(1,667	)	$	(1,985	)

(2) Operating expenses minus non-cash expenses
GAAP operating expenses as reported	$	2,211		$	2,198		$	4,690		$	4,642
Non-cash adjustments:
Stock-based compensation		(14	)		(130	)		(121	)		(307	)
Depreciation and amortization		(35	)		(45	)		(74	)		(90	)
Non-GAAP operating expenses minus non-cash expenses	$	2,162		$	2,023		$	4,495		$	4,245

Net loss adjusted for non-cash items and one-time events, or EBITDA loss, is a non-GAAP financial measure. The Company defines this as GAAP reported net loss minus depreciation and amortization, stock-based compensation, income taxes and non-cash foreign exchange transaction losses. The Company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect normal direct cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies.
Operating expenses minus non-cash expenses is a non-GAAP financial measure. The Company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies.

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
PRODUCT RELATED REVENUE SCHEDULES
(In thousands)
(Unaudited)

The following table shows our consolidated total revenue and revenue by geographic region for the three and six months ended September 30, 2024 and 2023:

	Three Months Ended September 30,
(In thousands)	2024		2023		$ Change			% Change
United States	$	675	$	590	$	85			14	%
Europe		1,506		1,201		305			25	%
Asia		776		346		430			124	%
Latin America		465		260		205			79	%
Rest of the World		157		334		(177	)		(53	%)
Total	$	3,579	$	2,731	$	848			31	%

	Six Months Ended September 30,
(In thousands)	2024		2023		$ Change			% Change
United States	$	1,317	$	1,396	$	(79	)		(6	%)
Europe		2,794		2,271		523			23	%
Asia		1,253		1,208		45			4	%
Latin America		1,345		747		598			80	%
Rest of the World		261		536		(275	)		(51	%)
Total	$	6,970	$	6,158	$	812			13	%

SOURCE: Sonoma Pharmaceuticals, Inc.

View the original press release on accesswire.com

FAQ

What was Sonoma Pharmaceuticals (SNOA) revenue growth in Q2 2025?

Sonoma Pharmaceuticals reported a 31% revenue growth in Q2 2025, reaching $3.6 million compared to $2.7 million in the same period last year.

How much did SNOA reduce its net loss in Q2 2025?

SNOA reduced its net loss by 59% in Q2 2025, from $1.5 million to $0.6 million compared to the same quarter last year.

What new regulatory approvals did SNOA receive in Q2 2025?

SNOA received a new FDA 510(k) clearance for its Microcyn technology-based solution on September 13, 2024, including specific over-the-counter indications for face, eyelid and eyelashes.

What was SNOA's cash position as of September 30, 2024?

SNOA reported cash and cash equivalents of $4.1 million as of September 30, 2024, an increase of $2 million compared to the same period last year.

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results